Ignyta Inc. (RXDX) 7.15 $RXDX
Ignyta Announces First Quarter 2014 Company Highlights and Financial Results
Business Wire - Mon May 12, 6:01AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2014.
Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting
Business Wire - Wed May 07, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that an abstract regarding the presentation of interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
PR Newswire - Mon May 05, 7:00AM CDT
Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire (CHRU) de Lille, France (Lille) and the Icahn School of Medicine at Mount Sinai (Mount Sinai). The consortium's goal is to identify the biological triggers that cause or lead to the development of inflammatory bowel disease (IBD). This first-of-its-kind, Pre-IBD Consortium brings together leading academic and industry experts to identify disease interception and prevention strategies for Crohn's disease and ulcerative colitis (UC).
Ignyta to Report 2014 First Quarter Company Highlights and Financial Results and Host Conference Call on May 12, 2014
Business Wire - Mon May 05, 6:01AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its first quarter 2014 financial results before the market opens on Monday, May 12, 2014. Ignyta management will host a conference call that same morning at 9:00 a.m. ET (6:00 a.m. PT) to provide company highlights, review the financial results and answer questions.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Ignyta Reports Granting of Inducement Awards
Business Wire - Tue Apr 01, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has issued inducement awards to three new non-executive employees.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Ignyta Announces Underwriters' Full Exercise of Option to Purchase Additional Shares in Public Offering of Common Stock
Business Wire - Mon Mar 17, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the underwriters' full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company's common stock, at a price to the public of $9.15 per share. The option to purchase the additional shares was granted in connection with the company's previously announced underwritten public offering of 5,245,000 shares of its common stock. The exercise of the option brings the expected total gross proceeds from the offering to approximately $55.2 million.
Ignyta prices public offering at USD9.15 per share
M2 - Fri Mar 14, 3:16AM CDT
Oncology company Ignyta (OTC BB:RXDX) said on Thursday that it has priced its public offering of 5,245,000 shares of its common stock.
Ignyta Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Mar 13, 7:07PM CDT
Ignyta, Inc., an oncology precision medicine biotechnology company, today announced the pricing of an underwritten public offering of 5,245,000 shares of its common stock at a public offering price of $9.15 per share, resulting in gross proceeds of approximately $48.0 million. In connection with the offering, shares of Ignyta common stock will commence trading on the NASDAQ Capital Market under the ticker symbol "RXDX" on March 14, 2014. In addition, Ignyta has granted the underwriters a 30-day option to purchase up to an additional 786,750 shares of common stock.
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Ignyta Announces 2013 Company Highlights and Full Year Financial Results
Business Wire - Fri Feb 28, 3:00PM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013.
Ignyta submits RXDX-101's NDA to FDA, seeking approval in treating metastatic cancer patients
M2 - Fri Feb 28, 3:42AM CST
Biotechnology company Ignyta (OTC BB:RXDX) disclosed on Thursday the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, RXDX-101.
Ignyta Announces Submission of IND for RXDX-101
Business Wire - Thu Feb 27, 8:01AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.
Ignyta to Report 2013 Company Highlights and Financial Results and Host Conference Call on February 28, 2014
Business Wire - Mon Feb 24, 6:00AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its 2013 financial results after the market closes on Friday, February 28, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results, and answer questions.
Ignyta Announces First Quarter 2014 Company Highlights and Financial Results
Business Wire - Mon May 12, 6:01AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2014.
Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting
Business Wire - Wed May 07, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that an abstract regarding the presentation of interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
PR Newswire - Mon May 05, 7:00AM CDT
Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire (CHRU) de Lille, France (Lille) and the Icahn School of Medicine at Mount Sinai (Mount Sinai). The consortium's goal is to identify the biological triggers that cause or lead to the development of inflammatory bowel disease (IBD). This first-of-its-kind, Pre-IBD Consortium brings together leading academic and industry experts to identify disease interception and prevention strategies for Crohn's disease and ulcerative colitis (UC).
Ignyta to Report 2014 First Quarter Company Highlights and Financial Results and Host Conference Call on May 12, 2014
Business Wire - Mon May 05, 6:01AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its first quarter 2014 financial results before the market opens on Monday, May 12, 2014. Ignyta management will host a conference call that same morning at 9:00 a.m. ET (6:00 a.m. PT) to provide company highlights, review the financial results and answer questions.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Ignyta Reports Granting of Inducement Awards
Business Wire - Tue Apr 01, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has issued inducement awards to three new non-executive employees.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Ignyta Announces Underwriters' Full Exercise of Option to Purchase Additional Shares in Public Offering of Common Stock
Business Wire - Mon Mar 17, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced the underwriters' full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company's common stock, at a price to the public of $9.15 per share. The option to purchase the additional shares was granted in connection with the company's previously announced underwritten public offering of 5,245,000 shares of its common stock. The exercise of the option brings the expected total gross proceeds from the offering to approximately $55.2 million.
Ignyta prices public offering at USD9.15 per share
M2 - Fri Mar 14, 3:16AM CDT
Oncology company Ignyta (OTC BB:RXDX) said on Thursday that it has priced its public offering of 5,245,000 shares of its common stock.
Ignyta Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Mar 13, 7:07PM CDT
Ignyta, Inc., an oncology precision medicine biotechnology company, today announced the pricing of an underwritten public offering of 5,245,000 shares of its common stock at a public offering price of $9.15 per share, resulting in gross proceeds of approximately $48.0 million. In connection with the offering, shares of Ignyta common stock will commence trading on the NASDAQ Capital Market under the ticker symbol "RXDX" on March 14, 2014. In addition, Ignyta has granted the underwriters a 30-day option to purchase up to an additional 786,750 shares of common stock.
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Ignyta Announces 2013 Company Highlights and Full Year Financial Results
Business Wire - Fri Feb 28, 3:00PM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013.
Ignyta submits RXDX-101's NDA to FDA, seeking approval in treating metastatic cancer patients
M2 - Fri Feb 28, 3:42AM CST
Biotechnology company Ignyta (OTC BB:RXDX) disclosed on Thursday the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, RXDX-101.
Ignyta Announces Submission of IND for RXDX-101
Business Wire - Thu Feb 27, 8:01AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.
Ignyta to Report 2013 Company Highlights and Financial Results and Host Conference Call on February 28, 2014
Business Wire - Mon Feb 24, 6:00AM CST
Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its 2013 financial results after the market closes on Friday, February 28, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results, and answer questions.
